Elevated serum plasminogen activator inhibitor-1 is associated with seizure burden, drug resistance, and neuroinflammatory markers in pediatric epilepsy - Scorecard - MDSpire
Advertisement
Elevated serum plasminogen activator inhibitor-1 is associated with seizure burden, drug resistance, and neuroinflammatory markers in pediatric epilepsy
Clinical Scorecard: Increased Levels of Serum Plasminogen Activator Inhibitor-1 Correlate with Seizure Frequency, Drug Resistance, and Neuroinflammatory Indicators in Children with Epilepsy
At a Glance
Category
Detail
Condition
Pediatric Epilepsy
Key Mechanisms
Neuroinflammation and blood-brain barrier disruption
Target Population
Children with epilepsy
Care Setting
Clinical research study
Key Highlights
Serum PAI-1 levels significantly elevated in epilepsy patients compared to controls.
PAI-1 correlates positively with seizure frequency and drug resistance.
PAI-1 is a potential diagnostic biomarker for epilepsy with an AUC of 0.916.
Higher PAI-1 levels are associated with neuroinflammatory markers and poorer quality of life.
PAI-1 may serve as a risk-stratification biomarker for treatment resistance.
Guideline-Based Recommendations
Diagnosis
Utilize PAI-1 levels as a biomarker for diagnosing epilepsy.
Management
Consider PAI-1 levels in assessing seizure burden and treatment resistance.
Monitoring & Follow-up
Monitor PAI-1 levels for potential changes in seizure frequency and treatment response.
Risks
Elevated PAI-1 levels may indicate increased risk of drug-resistant epilepsy.
Patient & Prescribing Data
Pediatric patients with epilepsy
Understanding PAI-1 levels may guide treatment strategies and risk assessment.
Clinical Best Practices
Incorporate PAI-1 level assessment in the clinical evaluation of pediatric epilepsy.
Use PAI-1 as a marker for monitoring neuroinflammation and seizure severity.
